Call for Papers: International Conference on Nanotechnologies and Biomedical Engineering (ICNBME)

7 - 8 July 2011, Chisinau, Republic of Moldova.
ICNBME-2011 continues the series of International Conferences in the field of nanotechnologies and biomedical engineering. The conference aims at bringing together scientists and engineers dealing with fundamental and applied research for reporting on the latest theoretical developments and applications in the fields involved.

Contributing papers are called in the following areas:

  • Nanotechnologies and Nanomaterials;
  • Micro- and Nano-objects, Nanostructured and highly integrated systems, Biophysics;
  • Plasmonics and Metamaterials;
  • Biomedical Optics and Lasers;
  • Sensors and Transducers;
  • Terahertz spectroscopy;
  • Biomedical Instrumentation and Devices;
  • Health Care Management;
  • Medical Imaging, Image and Signal Processing;
  • Radiation Protection and Dosymetry, Biological Effect of Radiation;
  • Biomedical Engineering Education;
  • Information Technologies for Health Care, Telemedicine and E-Health;
  • Other topics in biomedical engineering.

Submission of Papers
Contributed papers should be subscribed on four-six pages and submitted by e-mail in Microsoft Word format to This email address is being protected from spambots. You need JavaScript enabled to view it.

Accepted papers will be included in the Conference Proceedings, distributed to the participants at the beginning of the conference.

Deadlines:

  • May 1 st, 2011 - Submission of extended abstracts
  • May 15th, 2011 - Notification of acceptance
  • June 15th, 2011 - Advanced Conference Registration
  • June 20th, 2011 - Hotel/trip reservation
  • July 1th, 2011 --Deadline for Registration Fee refunding
  • July 5-6th, 2011 - Arrival and Registration of Participants
  • July 7th, 2011 - Opening of the Conference
  • July 9 th, 2011 - Social Program
  • July 9-10th, 2011 - Departure of Participants

For further information and registration, please visit:
http://www.icnbme.sibm.md

Most Popular Now

Imfinzi is the first immunotherapy to demonstrate …

AstraZeneca and MedImmune, its global biologics research and development arm, have presented data on overall survival (OS) in the Phase III PACIFIC trial of Imfinzi durin...

Sandoz Healthcare Access Challenge #SandozHACk ret…

Sandoz, the Novartis generics and biosimilars division, today announces the launch of the second Sandoz Healthcare Access Challenge (HACk). The #SandozHACk is a global co...

Global survey reveals that physicians need more in…

Results from a new global survey revealed that more than one-third (36%) of the 310 physicians surveyed do not think they have sufficient information required to make inf...

In clinical trials, new antibody therapy controls …

Thanks to improvements in antiretroviral therapy, HIV is now a manageable condition. Yet even the best drugs do not entirely eliminate the virus, which latently lingers i...

Novartis licenses three novel anti-infective progr…

Novartis announced today that it has entered into a licensing and equity agreement with Boston Pharmaceuticals for the development of three novel anti-infective drug cand...

The Nobel Prize in Physiology or Medicine 2018 was…

Cancer kills millions of people every year and is one of humanity's greatest health challenges. By stimulating the inherent ability of our immune system to attack tumor c...

Pfizer to award more than $3 million in grants to …

Pfizer Inc. today announced the recipients of the Advancing Science through Pfizer Investigator Research Exchange (ASPIRE) Breast Cancer Research Awards. Four grants tota...

FDA approves first treatment for advanced form of …

The U.S. Food and Drug Administration today approved Libtayo (cemiplimab-rwlc) injection for intravenous use for the treatment of patients with metastatic cutaneous squam...

DNA islands effective as 'anti-bacterial drones'

Genomic "islands" that evolved from viruses can be converted into "drones" that disable Staphylococcus aureus, bacteria that are often resistant to antibiotics and pose a...

FDA awards 12 grants to fund new clinical trials t…

The U.S. Food and Drug Administration today announced that it has awarded 12 new clinical trial research grants totaling more than $18 million over the next four years to...

Addressing social and cultural drivers of type 2 d…

New research shows healthcare services and public health strategies aimed at reducing the burden of type 2 diabetes may prove ineffective, unless they address social and ...

Evidence mounts linking aspirin to lower risk of o…

Taking a low-dose aspirin daily may help women lower their risk of developing ovarian cancer. A new study co-led by Moffitt Cancer Center found that women who reported ta...